	US 12,485,087 B2
	Use of encapsulated cell therapy for treatment of ophthalmic disorders
Jeffrey Louis Goldberg, San Diego, CA (US); Cahil Mcgovern, North Kingstown, RI (US); Weng Tao, Lincoln, RI (US); and Konrad A. Kauper, Sutton, MA (US)
Assigned to Neurotech USA, Inc., Cumberland, RI (US)
Filed by Neurotech USA, Inc., Cumberland, RI (US)
Filed on Nov. 1, 2024, as Appl. No. 18/934,892.
Application 18/934,892 is a continuation of application No. 18/527,884, filed on Dec. 4, 2023, granted, now 12,357,566.
Application 18/527,884 is a continuation of application No. 17/529,402, filed on Nov. 18, 2021, abandoned.
Application 17/529,402 is a continuation of application No. 16/563,048, filed on Sep. 6, 2019, granted, now 11,207,266, issued on Dec. 28, 2021.
Application 16/563,048 is a continuation of application No. 15/166,790, filed on May 27, 2016, granted, now 10,456,356, issued on Oct. 29, 2019.
Claims priority of provisional application 62/167,213, filed on May 27, 2015.
Prior Publication US 2025/0057760 A1, Feb. 20, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61F 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/30 (2015.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01)

CPC A61K 9/0051 (2013.01) [A61F 9/0017 (2013.01); A61K 9/4816 (2013.01); A61K 35/30 (2013.01); A61K 38/185 (2013.01); A61K 38/19 (2013.01); A61K 38/2066 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01)]

15 Claims

1. A method of treating macular telangiectasia in a patient suffering therefrom comprising: implanting into an eye of the patient a biocompatible device comprising

a) a core comprising between 5×10²and 6×10⁵ARPE-19 cells that are genetically engineered to secrete a therapeutically effective amount of ciliary neurotrophic factor (CNTF), wherein the therapeutically effective amount of CNTF is between 0.1 ng/eye/day and 50 ng/eye/day,

b) a semi-permeable membrane surrounding the core, wherein the membrane has a molecular weight cut off of 1-150 kD and permits the diffusion of the CNTF therethrough and wherein the semi-permeable membrane is between 90 and 120 μm thick, and

c) a matrix disposed within the semi-permeable membrane, wherein said matrix comprises monofilaments twisted into a yarn that is in non-woven strands, wherein the cells are distributed on the monofilaments, and wherein the monofilaments comprise polyethylene terephthalate;

wherein said biocompatible device produces therapeutically effective amounts of the CNTF for at least 12 months post implantation.